zoledronic acid has been researched along with Cardiovascular Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, T; Li, W; Ning, Z; Wang, J; Wang, M; Wen, A; Yang, Z; Yao, M; Zhang, W | 1 |
| Rizzoli, R; Uebelhart, B | 1 |
| Fulchino, LA; Kim, CA; Kim, DH; Kim, SC; Rogers, JR; Solomon, DH | 1 |
| John Camm, A | 1 |
4 review(s) available for zoledronic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies.
Topics: Aged; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Denosumab; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Systematic Reviews as Topic; Zoledronic Acid | 2022 |
[Osteoporosis].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium; Cardiovascular Diseases; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Rickets; Risk Factors; Zoledronic Acid | 2014 |
Bisphosphonates and risk of cardiovascular events: a meta-analysis.
Topics: Atrial Fibrillation; Bone Density Conservation Agents; Cardiovascular Diseases; Databases, Factual; Diphosphonates; Follow-Up Studies; Humans; Imidazoles; Myocardial Infarction; Odds Ratio; Osteoporosis; Risk; Stroke; Zoledronic Acid | 2015 |
Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
Topics: Animals; Atrial Fibrillation; Bone Density Conservation Agents; Cardiovascular Diseases; Diphosphonates; Female; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risk; Zoledronic Acid | 2010 |